Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) closed the day trading at $30.35 up 10.93% from the previous closing price of $27.36. In other words, the price has increased by $10.93 from its previous closing price. On the day, 1.6 million shares were traded. AMPH stock price reached its highest trading level at $30.63 during the session, while it also had its lowest trading level at $28.14.
Ratios:
For a better understanding of AMPH, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.03 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 12.58. For the most recent quarter (mrq), Quick Ratio is recorded 2.21 and its Current Ratio is at 3.29. In the meantime, Its Debt-to-Equity ratio is 0.87 whereas as Long-Term Debt/Eq ratio is at 0.85.
On May 12, 2025, JP Morgan Downgraded its rating to Neutral which previously was Overweight but kept the price unchanged to $30.
Piper Sandler Downgraded its Overweight to Neutral on February 04, 2025, whereas the target price for the stock was revised from $66 to $36.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 01 ’25 when Petersen Floyd F. sold 500 shares for $20.83 per share. The transaction valued at 10,416 led to the insider holds 77,031 shares of the business.
Petersen Floyd F. bought 500 shares of AMPH for $10,430 on Aug 01 ’25. On Jul 02 ’25, another insider, Petersen Floyd F., who serves as the Director of the company, sold 500 shares for $23.47 each. As a result, the insider received 11,734 and left with 77,531 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMPH now has a Market Capitalization of 1411126272 and an Enterprise Value of 1834871552. As of this moment, Amphastar’s Price-to-Earnings (P/E) ratio for their current fiscal year is 11.36, and their Forward P/E ratio for the next fiscal year is 8.09. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 5.49. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.95 while its Price-to-Book (P/B) ratio in mrq is 1.86. Its current Enterprise Value per Revenue stands at 2.539 whereas that against EBITDA is 7.751.
Stock Price History:
The Beta on a monthly basis for AMPH is 0.76, which has changed by -0.28487277 over the last 52 weeks, in comparison to a change of 0.18157876 over the same period for the S&P500. Over the past 52 weeks, AMPH has reached a high of $53.96, while it has fallen to a 52-week low of $20.39. The 50-Day Moving Average of the stock is 28.94%, while the 200-Day Moving Average is calculated to be -3.37%.
Shares Statistics:
Over the past 3-months, AMPH traded about 517.97K shares per day on average, while over the past 10 days, AMPH traded about 768580 shares per day. A total of 46.49M shares are outstanding, with a floating share count of 34.10M. Insiders hold about 26.65% of the company’s shares, while institutions hold 73.17% stake in the company. Shares short for AMPH as of 1753920000 were 4024867 with a Short Ratio of 7.77, compared to 1751241600 on 4062426. Therefore, it implies a Short% of Shares Outstanding of 4024867 and a Short% of Float of 17.39.
Earnings Estimates
A comprehensive evaluation of Amphastar Pharmaceuticals Inc (AMPH) is underway, with the input of 6.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $0.9, with high estimates of $1.1 and low estimates of $0.68.
Analysts are recommending an EPS of between $3.57 and $3.03 for the fiscal current year, implying an average EPS of $3.32. EPS for the following year is $3.75, with 6.0 analysts recommending between $4.81 and $3.29.
Revenue Estimates
5 analysts predict $185.67M in revenue for the current quarter. It ranges from a high estimate of $193.9M to a low estimate of $177.1M. As of the current estimate, Amphastar Pharmaceuticals Inc’s year-ago sales were $191.21MFor the next quarter, 5 analysts are estimating revenue of $193.82M. There is a high estimate of $210.8M for the next quarter, whereas the lowest estimate is $181M.
A total of 6 analysts have provided revenue estimates for AMPH’s current fiscal year. The highest revenue estimate was $749.6M, while the lowest revenue estimate was $710M, resulting in an average revenue estimate of $724.55M. In the same quarter a year ago, actual revenue was $731.97MBased on 6 analysts’ estimates, the company’s revenue will be $769.45M in the next fiscal year. The high estimate is $885.5M and the low estimate is $726M.
